Bristol Myers Squibb's investment focus is strategically aligned with its core therapeutic areas, including immunology, oncology, hematology, neuroscience, and radiopharma, aiming to advance innovative medicines and commercialize critical assets. Their strategy involves forming new ventures with investment firms to develop specific drug candidates, divesting non-core assets, and making strategic investments in life science startups and supporting biotech incubators.
84% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Their most common stage is series-b (53% of deals). Average disclosed round size is $93.1M (across 16 rounds with reported amounts).
Portfolio
19
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Precede Biosciences | Series B | $63.5M | Jan 2026 |
 Link Cell Therapies | Series A | $60M | Dec 2025 |
 Aktis Oncology | Series B | $175M | Sep 2024 |
 Abata Therapeutics | Unknown | — | Aug 2024 |
 Outpace Bio | Series B | $144M | Aug 2024 |
 Envisagenics | Series B | — | Jun 2024 |
| CCOUR Pharmaceuticals | Series A | $105M | Jan 2024 |
 Ratio Therapeutics Inc. | Series B | $50M | Jan 2024 |
 GlycoEra AG | Series A | — | Jan 2024 |
| Precede Biosciences | Series A | $57M | Oct 2023 |
 AstronauTx Ltd. | Series A | $61M | Oct 2023 |
 Cellares | Series C | $255M | Aug 2023 |
| CCajal Neuroscience | Series A | $96M | Nov 2022 |
 Sapience Therapeutics, Inc. | Series B | $41M | May 2022 |
| TTreeFrog Therapeutics | Series B | $75M | Sep 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
| Aktis Oncology | Series A | $72M | Mar 2021 |
 Personal Genome Diagnostics Inc. (PGDx) | Series B | $75M | Jan 2018 |
 Blade Therapeutics | Series B | $45M | Jun 2016 |
Top Co-Investors
Last updated: 12 April 2026